NeoStem, Inc. , a leader in the emerging cellular therapy industry, announced today that the United States Adopted Name Council has approved the generic name "eltrapuldencel-T" for the Company's patient-specific targeted cancer immunotherapy under investigation for the treatment of Stage IV or recurrent Stage III metastatic melanoma. This investigational treatment, planned to be evaluated in the Company's Phase 3 Intus study, has been granted Orphan Drug and Fast Track designations by the U.S. Food and Drug Administration and will be conducted under a protocol that has been granted Special Protocol Assessment .
http://www.biospace.com/news_story.aspx?StoryID=348951&full=1
http://www.biospace.com/news_story.aspx?StoryID=348951&full=1
No comments:
Post a Comment